The histology diagnostic method involves microscopic evaluation of gastric biopsy specimens that are obtained during endoscopy. By the use of hematoxylin-eosin, Giemsa, Warthin-Starry or immunohistochemical stains tissue sections are stained to visualise H. pylori organisms and hence assess gastric mucosal pathology [12]-[14]. The strengths of histology are that it offers a direct visualisation of H. pylori organisms, and at the same time, it assesses gastritis, intestinal metaplasia, atrophy, malignancy risks and dysplasia. When sufficient biopsy sampling and staining techniques are used, the histology method exhibits high sensitivity and specificity [14][15]. The limitation of the histology diagnostic method is that the accuracy of diagnosis may be affected by a recent proton pump inhibitor (PPI) use, patchy bacterial distribution, gastrointestinal bleeding, antibiotic exposure and inadequate biopsy sampling. Also, histology highly demands experienced pathologists and access to endoscopic facilities [16]. Clinically, the histology diagnostic method is more useful for patients who require mucosal assessment, such as those with suspected gastric cancer, premalignant gastric lesions and peptic ulcer disease [13]. The rise of artificial intelligence has led to the development of artificial intelligence-assisted pathology, which has shown promising results in improving diagnostic consistency and reducing interobserver variability [17].

The rapid urease test operates by detecting urease enzyme activity that is produced by H. pylori organisms. Gastric biopsy specimens are placed in a medium containing urea with a pH indicator. Therefore, the hydrolysis of urea occurs to produce ammonia, resulting in a colour change [18][19]. The rapid urease test is inexpensive, fast, simple and widely available; its results are often obtained within hours. In some instances, false-negative results may occur in patients with low bacterial density, recent proton pump inhibitor use, recent antibiotic use, intestinal metaplasia, gastrointestinal bleeding, or atrophic gastritis. In addition, the RUT method doesn’t provide any information regarding antimicrobial susceptibility or mucosal pathology. The rapid urease test is most commonly used during a routine endoscopy to confirm the infection rapidly [20]. In recent findings, microfluidic-based urease detection platforms and combined molecular confirmation approaches may improve the diagnostic sensitivity [20][21].

The culture diagnostic approach involves the isolation of H.pylori from gastric biopsy specimens using a selective medium under microaerophilic conditions [22][23]. The culture remains the only conventional diagnostic method that allows phenotypic antimicrobial susceptibility testing. This is particularly valuable in patients with treatment failure or suspected antibiotic resistance [24]. This method is technically challenging, requires significant time, and is less sensitive compared to many other diagnostic techniques. Its effectiveness heavily depends on specimen handling, transport conditions, bacterial load, and the skill of the laboratory personnel [25][26]. The culture is primarily used in refractory infection, resistance surveillance programs and specialized clinical or research settings [8]. In recent findings, automated culture systems and improved transport media have been developed to improve recovery and reduce turnaround times.

Polymerase chain reaction exhibits high specificity and sensitivity, including samples with low bacterial load. PCR combines high analytical sensitivity with the ability to detect clarithromycin-resistance mutations, but performance still depends on specimen type, primer design, and laboratory capacity [27]-[29]. The evidence here splits into diagnostic accuracy, resistance detection, and practical limitations plus newer molecular extensions. PCR generally detects H. pylori with high sensitivity and specificity in biopsy-based testing, and several studies report performance above 95% [27][28]. Real-time PCR outperformed rapid urease testing in one prospective biopsy study, detecting 97.1% of infected specimens versus 82.9% for RUT [30]. Multiplex PCR assays also performed strongly, with Allplex showing 99.2% sensitivity and 100% specificity against sequencing in gastric biopsies [31]. ddPCR can detect low-density infection missed by conventional tests, including 36% of patients classified negative by standard methods in one gastric-biopsy study [32]. PCR is especially valuable because it can identify resistance-associated mutations while confirming infection, most often clarithromycin resistance linked to 23S rRNA variants [31][33][34]. Real-time PCR can classify clarithromycin resistance with good concordance to phenotype, including 95% concordance in LightMix testing and 87.5% accuracy for resistant genotypes in a 410-biopsy study [33][35]. PCR can also reveal heteroresistance or minor resistant subpopulations that culture may miss. Overall, the literature supports the statement that PCR is a high-performance method for H. pylori detection and clarithromycin resistance profiling, particularly in biopsy samples, while also showing that cost, infrastructure, contamination control, and specimen-dependent variability limit universal use [36][37].

The Urea breath test detects urease activity by measuring exhaled labelled carbon dioxide after ingestion of Carbon-13 or carbon-14 labelled urea [40]. UBT is considered one of the most accurate non-invasive tests for detecting active infection and for post-eradication confirmation. Sensitivity and specificity generally exceed 90% under appropriate testing conditions [41]. Recent use of antibiotics, PPIs, or bismuth compounds may reduce the bacterial load and lead to false-negative results. The method also requires specialized equipment [11]. UBT is widely recommended for both initial diagnosis and for confirming eradication after treatment [18]. In recent findings, portable infrared spectrometry systems and simplified testing protocols have improved accessibility in resource-constrained settings [41].

The stool antigen test detects H. pylori antigens shed into the gastrointestinal tract using enzyme immunoassays or immunochromatographic assays [42]. Monoclonal antibody-based SATs demonstrate high sensitivity and specificity comparable to UBT. The method is relatively inexpensive and suitable for both adults and children [43]. Diagnostic accuracy may be reduced by improper stool handling, recent antibiotic exposure, or use of PPIs and bismuth compounds [44]. SAT is recommended for both initial diagnosis and post-treatment confirmation, particularly in settings where UBT is unavailable [44]. In recent findings, rapid immunochromatographic assays and improved monoclonal antibody platforms have enhanced test reliability [44][45].

Serological tests detect IgG antibodies to H. pylori in blood samples via ELISA, immunoblot or rapid immunochromatographic tests. Multiple assays can measure antibodies to many H pylori proteins (e.g., CagA, VacA, GroEL, HcpC) simultaneously in the sample [43][46]. Serology is inexpensive, widely available, and unaffected by recent antibiotic or PPI use [43]. Antibodies may persist long after eradication, making serology unable to distinguish between active and previous infection. Consequently, specificity for active infection is relatively low [47]. Serology may still be useful in epidemiological studies or in settings where other diagnostic methods are unavailable [48]. In recent findings, research continues into antigen-specific serological markers for virulence-associated proteins such as CagA and VacA [49].

Histology generally exhibits a higher rate of sensitivity than culture, especially in cases where there is low bacterial density. However, culture remains uniquely valuable because it enables antimicrobial susceptibility testing and isolation of visible organisms [9]. Across studies, histology usually matches or exceeds culture in the detection of H. pylori although both methods vary due to laboratory conditions, sampling and operator expertise [50]-[53]. Histology reached 94.1% sensitivity versus 95.2 for culture in one large 2025 cohort, showing both can perform well in optimized practice [51]. Other studies found histology higher including 96.6% versus 20.7% in children and 73.3% versus 74.4% in routine workflow where both conventional methods underperformed PCR [50][52]. Table 1 shows the comparison of histology and culture for biopsy-based H. pylori detection. Therefore, the literatures suggest that histology is usually more sensitive for detection especially when organism burden is low while culture is indispensable for susceptibility testing and strain isolation hence histology is a detection plus tissue test whereas culture is a detection plus isolate test [52][53].

Table 1.Comparison of histology and culture for biopsy-based H. pylori detection.

RUT is cheaper, faster, and simpler than histology; however, histology provides additional information on mucosal inflammation, intestinal metaplasia, atrophy, and dysplasia [11][21]. Table 2 shows comparison of histology and rapid urease test for H. pylori detection. Across studies, both tests usually show a good performance but accuracy varies widely by biopsy site, reference standard and patient population. A systematic study review conducted in 2023 concluded that neither of the test alone is a gold standard and performance varies by clinical situation [18]. Histology from antrum plus corpus reached 95.1% sensitivity and 95.1% specificity in one review table while combined site RUT reached 86.6% sensitivity and 100% specificity [18]. RUT accuracy ranged from strong in some studies, such as 94% - 95% sensitivity or accuracy to clearly weaker in others including 75% sensitivity and 32% sensitivity when compared with histology on one Saudi cohort [55]-[57]. The main reason histology and RUT differ depends on urease activity, so anything that suppresses bacteria or enzyme activity can reduce sensitivity. Histology can miss infection but it can be strengthened with special strains and can reveal mucosal pathology beyond organism detection [18][58]. PPI use is repeatedly linked to false-negative RUT results, in one study 75% of false negative RUT cases had PPI exposure [59]. Histology identified additional infections missed by RUT, including 15 extra positives in 612 cases endoscopy and 33% detection increase when combined with RUT [59][60]. Therefore, histology versus rapid urease testing in H. pylori detection is quite a complicated comparison because histology is usually more comprehensive and more reliable when RUT is negative or mucosal assessment matters while RUT remains fast, inexpensive option with good performance in many routine settings [39][61][62].

Table 2. Comparison of histology and rapid urease test for H. pylori detection.

Table 3.Comparison of urea breath test and stool antigen test for H. pylori detection.

Both the Urea Breath Test and the monoclonal Stool Antigen Test exhibit excellent diagnostic performance for active infection. However, the Urea Breath Test is considered more accurate than other non-invasive tests, whereas the Stool Antigen Test is the most cost-efficient and more practical in many low-resource settings [46]. Table 3 shows comparison of urea breath test and stool antigen test for H. pylori detection. 13C urea breath test has the strongest overall evidence for higher diagnostic accuracy than stool antigen testing, with a Cochrane review finding higher diagnostic odds ratio and sensitivity at a fixed specificity although direct head to head comparison were limited [11]. Monoclonal stool antigen test can reach high accuracy and in some cohorts perform similarly to urea breath testing, especially in children or with optimized assays, but results vary by assay and setting [45][67]-[69]. Older or some real world stool antigen tests often show lower sensitivity than urea breath testing, with several direct comparisons reporting more false negatives for stool testing [41][63][70]. Urea breath testing is better supported choice when the question is which tests active H. pylori more accurately overall. Stool antigen testing remains a credible non-invasive alternative especially with monoclonal assay, lower resource setting and some pediatric or screening contexts [71].

Table 4. Comparison of urea breath test and serology for H. pylori detection.

The Urea Breath Test exhibits higher specificity for active infection than serology. However, unlike serology, the Urea Breath Test is suitable for post-eradication confirmation [72]. Table 4 shows a comparison of urea breath test and serology for H. pylori detection. Indirect comparison and meta analyses UBT has the stronger overall evidence base for current infection while serology remains useful when access, cost or prior medication matter [10][11][73]. UBT outperforms serology for detecting active H. pylori in the largest comparative synthesis, across 101 studies 13C-UBT had an estimated sensitivity of 94% at fixed specificity versus 84% for serology with fewer negatives [11]. Serology still has screening value in some lower prevalence settings because sensitivity can be high and negative value can be strong, but positive results do not distinguish current from past infection [41][73][74]. Not every dataset favors UBT on sensitivity alone. A 2020 health system analysis using histopathology as reference found serology sensitivity 0.94 versus 0.64 for UBT then proposed serology first reflex algorithms to reduce diagnostic error in that population [72]. A 2024 population level comparison also found serology sensitivity of 96.5% and NPV of 98.4% versus UBT supporting serology as initial rule out test in lower prevalence settings [75]. But serology remains limited by what it measures, it often reflects prior exposure rather than active infection and agreement with UBT worsens after eradication therapy [10], [76]. Urea breath test versus serology therefore favors UBT for diagnosing current H. pylori infection and for post treatment follow up while serology still has a narrower role as low cost, accessible screening or rule out test in selected populations.

The Stool Antigen Test is more efficient than serology for both post-treatment and active infection. In pediatric populations, the Stool Antigen Test is preferred for its strong diagnostic performance and practicality. Stool antigen test is cheaper and often easier for primary care, children and lower resource settings, its performance depends more on sample handling, antigen stability and bacterial load [24], [44][45]. While UBT is widely treated as preferred non-invasive test but needs fasting, patient time and specialized equipment [11][80]. Older biopsy based follow up data favored UBT after eradication therapy, overall 97% for 13C-UBT versus 88% for HpSA with more false positives for stool antigen testing [81]. More recent studies show this gap is not universal. UBT and stool antigen testing had 87% agreement in one Jordan eradication cohort, 96% concordance in an Italian monoclonal stool test study and complete agreement with biopsy test in small Japanese pediatric follow up sample [41][68][70]. For Urea Breath Test versus Stool antigen test, the overall literature leans towards UBT for the most reliable diagnosis of active infection and for eradication confirmation but the difference narrows substantially when stool testing uses well validated monoclonal assay and local logistics favor stool-based testing.

For younger patients with uninvestigated dyspepsia and no alarm features, the literature consistently supports a test and treat strategy using non-invasive testing rather than immediate endoscopy [82][83]. Urea breath testing and stool antigen testing are the main non-invasive options recommended for primary diagnosis, while serology is limited because it does not distinguish active from passive infections [1][10][84]. 13c-UBT had the highest pooled non-invasive accuracy in a Cochrane review with sensitivity 0.94 at specificity 0.9 [11]. Also Monoclonal SAT supports first line use with reviews describing high accuracy and frequent sensitivity/specificity above 90% [45][85].

The alarming features, such as gastrointestinal bleeding, anemia, weight loss or malignancy suspected shifts evaluation to endoscopy with biopsy based testing [82][86][87].

For post-eradication confirmation, the key principle is to use tests that detect active infection which favors UBT and stool antigen over serology [45][84][88]. Pediatric evidence is more nuanced: non-invasive tests are useful for confirming eradication but routine test and treat strategies for children are not recommended because the diagnostic goal is to explain symptoms, not simply detect colonization. Testing should usually take place at least four weeks post-therapy and after stopping PPIs [89]-[91].

Repeated treatment failure changes the diagnostic goal from simple detection to resistance profiling. In that setting, culture and molecular methods become especially valuable because they can guide susceptibility based therapy although they usually require biopsy access or specialized laboratories [84][91]. In low resource setting, feasibility matters as raw accuracy, so stook antigen testing often offers the best practical compromise when endoscopy, UBT or molecular testing are hard to access [71][82][92]. Culture remains the reference method for susceptibility testing but needs endoscopy and dedicated laboratory support [82][91]. Molecular assays are useful mainly for detecting antibiotic resistance, including on gastric biopsy specimens [91]. And in constrained settings, SAT is attractive because it is cheaper that UBT and still useful before and after eradication treatment [45][71][88].

Therefore, scenario-based H. pylori diagnosis is the best approach whereby the choice of the method depends on clinical risk, age and local resources. For personal diagnositic decisions the evidence should be applied by licensed clinician who can account for symptoms, medication washout and local test performance.

Drug exposure is the most consistently reported cause of reduced H. pylori test sensitivity, particularly for UBT, SAT, histology, RUT, and culture [94]-[96]. Reviews specifically link PPIs, antibiotics, and bismuth to false-negative results by lowering bacterial load. Histology is also affected by PPI exposure, and multiple sources state that PPIs should be stopped for 2 weeks before biopsy-based testing [1][86][97]. UBT is more vulnerable to acid suppression than SAT in several studies [98][99]. In one medication-interference study, lansoprazole caused false-negative UBTs in 30% - 40% and bismuth in 45% - 55%; SAT false negatives were lower at 15% - 25% and 10% - 15% [96]. Although some newer SAT assays retained high sensitivity during PPI use, these data are assay-specific rather than universal [98][99].

Patchy gastric colonization lowers the sensitivity of biopsy-based tests, so inadequate site selection or too few biopsies can produce false negatives. Multiple reviews recommend sampling from both antrum and corpus, often with at least two biopsies from each site, to reduce sampling error. Test performance also depends on technical handling: culture sensitivity drops when biopsy transport is delayed or specimens are exposed to aerobic conditions. Recent eradication therapy lowers sensitivity across tests, and real-world data show reduced detection after prior treatment history. Exclusion and washout rules in diagnostic studies commonly require PPI cessation for 2 weeks and antibiotic or bismuth cessation for 4 weeks before UBT or SAT. Reading a rapid urease test too early can itself create a false negative [1][86][95][100][101].

Low bacterial load is a central mechanism linking several patient factors to poor test performance [50][102]. Atrophic gastritis, intestinal metaplasia, bleeding, gastric cancer, and MALT lymphoma are repeatedly associated with reduced sensitivity, especially for conventional invasive tests and for UBT/SAT in advanced gastric pathology [95][102]. In atrophy, bacterial density can fall markedly or disappear, which lowers histology, culture, and urease-test sensitivity [1][50]. Upper GI bleeding often reduces test sensitivity, though newer observational data show some inconsistency by population and bleed definition [94][95][97]. Histology and culture perform much better when bacterial load is high, with sensitivities exceeding 90% in high-load biopsies in one large workflow study. Molecular testing on biopsy appears less vulnerable to low culture yield and can improve detection plus resistance profiling [50].

Overall, the literature supports the washout rule you stated: stop PPIs for about 2 weeks and antibiotics or bismuth for about 4 weeks before testing whenever feasible [1][95][100]. For personal testing decisions, a licensed clinician should interpret these factors in the context of symptoms, bleeding risk, recent therapy, and the specific assay being used.